NCT00923234: Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes |
|
|
| Terminated | 1 | | Europe | Azacitidine, Vidaza, Lenalidomide, Revlimid | Technische Universität Dresden, Celgene Corporation | Myelodysplastic Syndromes, Acute Myelogenous Leukemia | 07/12 | 07/12 | | |
